Tech Company Financing Transactions
Avaxia Biologics Funding Round
Avaxia Biologics, based in Lexington, secured $2.9 million from private investors.
Transaction Overview
Company Name
Announced On
12/23/2013
Transaction Type
Debt
Amount
$2,872,388
Round
Undisclosed
Investors
Proceeds Purpose
Proceeds purposes were not disclosed. SEC regulatory filing. Contact technology company for solicitation details, if applicable.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
128 Spring St. 620
Lexington, MA 02421
USA
Lexington, MA 02421
USA
Phone
Website
Email Address
Overview
Avaxia Biologics develops orally-delivered antibody therapeutics using a proprietary antibody platform.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Barbara Fox
Chief Financial Officer
David Neafus
VP - Operations
Neil Schauer
Browse more venture capital transactions:
Prev: 12/23/2013: Aviary venture capital transaction
Next: 12/23/2013: GreenLight Biosciences venture capital transaction
Share this article
About Our VC Transactions Data
We record every notable VC transaction. All VC database entries on this site are derived from a variety of public sources. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs